Search results
Showing 901 to 950 of 2053 results for work
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
or how to assess it, and administering the questionnaire might need extra work and time. However, it is patient-administered and easy to...
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.
This quality standard covers diagnosing and managing bladder cancer in adults (aged 18 and over) referred from primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS106Show all sections
Sections for QS106
- Quality statements
- Quality statement 1: Obtaining detrusor muscle during transurethral resection of bladder tumour
- Quality statement 2: Chemotherapy during transurethral resection of bladder tumour
- Quality statement 3: Access to a clinical nurse specialist
- Quality statement 4: Risk classification
- Quality statement 5: Discussing treatment options for high-risk non-muscle-invasive bladder cancer
- Quality statement 6: Discussing treatment options for muscle-invasive urothelial bladder cancer
- Quality statement 7: Discharge to primary care
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS164Show all sections
Sections for QS164
- Quality statements
- Quality statement 1: Point of contact with specialist services
- Quality statement 2: Information about impulse control disorders
- Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy
- Quality statement 4: Levodopa in hospital or a care home
- Quality statement 5: Access to clozapine for treating hallucinations and delusions
- About this quality standard
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
and half of trusts have community mental health rehabilitation teams who work with people after they have left hospital and moved to...
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.
assessment processpractitioners from teams across health and social care need to work together on carers' assessments, but they do not...
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)
NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .
NHS OpenAthens eligibility covers a wide range of those working in health and care, including all staff employed by NHS Trusts. Resources are for users in England only.
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more.
This quality standard covers diagnosing, assessing and treating community-acquired and hospital-acquired pneumonia in babies over 1 month (corrected gestational age), children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover ventilator associated pneumonia or COVID-19 pneumonia.
View quality statements for QS110Show all sections
Sections for QS110
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.
View quality statements for QS70Show all sections
This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.
View quality statements for QS145Show all sections
Sections for QS145
- Quality statements
- Quality statement 1: Follow-up invitations
- Quality statement 2: Offering outstanding vaccinations
- Quality statement 3: Recording vaccinations
- Quality statement 4: Checking immunisation status at specific educational stages
- Quality statement 5: Checking immunisation status of young offenders and offering outstanding vaccinations
- Update information
- About this quality standard
In development Reference number: GID-TA11278 Expected publication date: TBC
effective, therefore it is important to know whether similar interventions will work with other populations. Even less evidence is...
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Difelikefalin for treating pruritus in people having haemodialysis (TA890)
Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis.
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant
In development Reference number: GID-HTE10084 Expected publication date: TBC
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
This quality standard covers diagnosing and managing type 1 and type 2 diabetes in children and young people (under 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS125Show all sections
Sections for QS125
- Quality statements
- Quality statement 1: Same-day referral and appointments
- Quality statement 2: Education and information
- Quality statement 3: Intensive insulin therapy and level 3 carbohydrate-counting education for type 1 diabetes
- Quality statement 4: Continuous glucose monitoring in type 1 diabetes
- Quality statement 5: Blood ketone monitoring in type 1 diabetes
- Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes
- Update information
surgeon can discuss this option with you if you wish. 3 Which type of surgery works best, and which has the most complications? There's...
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals.
Pembrolizumab for previously treated endometrial cancer [ID1205]
Discontinued Reference number: GID-TA10243
Discontinued Reference number: GID-TA10836
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued Reference number: GID-TA10617
Discontinued Reference number: GID-TA10937
Discontinued Reference number: GID-TA10965